Clinical trials: Lymph Node Metastasis
Breast Neoplasms, Breast Diseases
Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer
This is a study to evaluate the incidence of sampling bias during pathologic assessment of sentinel lymph nodes (SLN) when they are cut at a certain thickness (1 mm) and the tissue slices are completely analyzed by histopathology…
- Trial name
- NCT01140763
- Testing
- Sysmex's 5-blade lymph node cutter
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Sysmex America, Inc.
Breast Cancer
GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study
This post-approval study is designed to determine the performance of the FDA-approved GeneSearch™ BLN Assay when compared to the site's standard of care permanent section histological evaluation, and when compared to more…
- Trial name
- NCT00595296
- Testing
- GeneSearch™ Breast Lymph Node (BLN) Assay
- Where
- 6 sites in United States
- Volunteers
- 461 people
- Sponsor
- Janssen Diagnostics, LLC
Secondary Lymphedema
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
This study evaluates the efficacy of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer by comparing the effects of active study treatment Lymfactin® to placebo.
- Trial name
- AdeLE (NCT03658967)
- Testing
- Lymfactin® (1x10E11 vp)
- Where
- 5 sites in Finland, Sweden
- Volunteers
- 39 people
- Sponsor
- Herantis Pharma Plc.
Hepatocellular Carcinoma, Liver Metastases
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
This is a phase 1b/2, multicenter, open-label, basket trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors alone and in combination with systemic intravenous (IV) administration of…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
- Trial name
- MASTERKEY-318 (NCT02509507)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 127 people
- Sponsor
- Amgen